The deal is virtually assured to pass given Sponsor control (~70.5%). Key risk is the earnout threshold ($42.7M revenue in 2026) given CubeBio has zero revenue and a delayed commercialization timeline. Monitor for redemption levels and Nasdaq listing approval post-vote.
Price Chart
Executive Summary
Mountain Crest Acquisition Corp. V (MCAG) is seeking stockholder approval for its business combination with CubeBio Co., Ltd., a South Korean early cancer detection company. The deal values CubeBio at $375 million, with CubeBio shareholders receiving approximately 37.5 million PubCo ordinary shares (90% of pro forma ownership) and existing MCAG public shareholders receiving about 1.8% post-closing. The SPAC has only ~$862K in trust, and the combined entity will have negative book value per share. The Sponsor, owning ~70.5% of MCAG, has agreed to vote in favor, making approval virtually certain. The deal includes an earnout of 24.5 million shares if CubeBio achieves $42.7M revenue in 2026, but CubeBio has no revenue to date and its regulatory/commercialization timeline extends to 2027+.
Key Financial Metrics
Key Facts
- Special meeting scheduled for November 11, 2026 to vote on the business combination with CubeBio.
- CubeBio is a pre-revenue South Korean diagnostics company developing urine-based early cancer detection tests (ONCOtunity and ONCOtunity-P).
- CubeBio had net losses of ~$4.25M (2025) and ~$5.58M (2024) and has generated no revenue to date.
- The deal values CubeBio at $375 million, with CubeBio shareholders receiving ~37.5M PubCo shares (~90% of pro forma ownership).
- Existing MCAG public shareholders will hold only ~1.8% of the combined company post-closing.
- As of September 14, 2026, the trust account held only ~$862K; estimated redemption price is ~$11.95 per share.
- Pro forma book value per share is negative ($0.02 to $0.05) under all redemption scenarios.
- The Sponsor (Mountain Crest Global Holdings LLC) owns ~70.52% of MCAG and has agreed to vote all shares in favor.
- An earnout of 24.5 million PubCo shares is contingent on CubeBio achieving $42.7M revenue in fiscal 2026.
- CubeBio's projected 2025 revenue of $5.7M was not achieved; it now expects RUO sales to commence in 2027.
- PubCo intends to list on Nasdaq under the symbol KUBE, but listing is not guaranteed.
- The Board unanimously recommends voting FOR all proposals.
Financial Impact
CubeBio valued at $375M; SPAC trust has ~$862K; combined entity has negative book value per share ($0.02-$0.05).
Risk Factors
- CubeBio has no revenue and significant net losses; commercialization timeline extends to 2027+.
- Earnout threshold of $42.7M revenue in 2026 appears highly unlikely given current stage.
- Pro forma negative book value indicates weak financial position post-closing.
- Nasdaq listing for PubCo (KUBE) is not guaranteed; MCAG currently trades on OTC Pink.
- CubeBio's India distribution agreement was suspended due to breach of contract.
- Significant dilution from 24.5M earnout shares (36.7% of total shares outstanding).
Investment Themes
Documents Analyzed
This report is based on 2 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| DEFM14A Filing (Primary) | 0001829126-26-011337 |
| Document: mountaincrest5_defm14a.htm | 0001829126-26-011337 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 20, 2026 6d ago | DEFM14A | $13.27 | awaiting T+20 | — | $13.27 (+0.00%) |
Oct 14, 2026 11d ago | DEF 14A | $13.27 | awaiting T+20 | — | $13.27 (+0.00%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers